Pranav S Garimella1, Traci M Bartz2, Joachim H Ix3, Michel Chonchol4, Michael G Shlipak5, Prasad Devarajan6, Michael R Bennett6, Mark J Sarnak7. 1. Tufts Medical Center, Boston, MA. Electronic address: pgarimella@ucsd.edu. 2. University of Washington, Seattle, WA. 3. University of California San Diego, San Diego, CA. 4. University of Colorado, Denver, CO. 5. San Francisco VA Medical Center and the University of California San Francisco, San Francisco, CA. 6. University of Cincinnati, Cincinnati, OH. 7. Tufts Medical Center, Boston, MA.
Abstract
BACKGROUND: Laboratory studies suggest that urinary uromodulin, the most common protein in the urine of healthy adults, may protect against urinary tract infection (UTI). Epidemiologic studies evaluating this relationship in humans are lacking. STUDY DESIGN: Prospective longitudinal cohort study. SETTING & PARTICIPANTS: 953 participants enrolled in the Cardiovascular Health Study. PREDICTOR: Uromodulin assayed using enzyme-linked immunosorbent assay in spot urine samples. OUTCOMES: Composite of outpatient UTI events or UTI-related hospitalizations and each of them individually identified using International Classification of Diseases, Ninth Revision (ICD-9) codes using negative binomial regression with robust standard errors adjusted for age, race, sex, body mass index, diabetes, estimated glomerular filtration rate, and urinary albumin and urinary creatinine excretion. RESULTS: Median uromodulin level was 25.9 (IQR, 17.3-38.9) μg/mL, mean age of participants was 78 years, 61% were women, and 15% were black. There were 331 outpatient UTI events and 87 UTI-related hospitalizations among 186 participants during a median 9.9 years of follow-up. Persons in the highest quartile (>38.93μg/mL) of uromodulin concentration had a significantly lower risk for the composite outcome (incidence rate ratio [IRR], 0.47; 95% CI, 0.29-0.79) compared with those in the lowest quartile (≤17.26μg/mL). This association remained significant for outpatient UTI events (highest vs lowest quartile even after excluding those with prior UTI: IRR, 0.42; 95% CI, 0.23-0.77). The direction of association with UTI hospitalization was similar, but not statistically significant (IRR, 0.78; 95% CI, 0.39-1.58). LIMITATIONS: Use of ICD-9 codes to identify outcomes and lack of generalizability to younger populations. CONCLUSIONS: High urinary uromodulin levels are associated with lower risk for UTI in older community-dwelling adults independent of traditional UTI risk factors. This finding supports prior laboratory data indicating a protective role of uromodulin against UTI. Further research is needed to understand if this may lead to new treatments to prevent or treat UTI.
BACKGROUND: Laboratory studies suggest that urinary uromodulin, the most common protein in the urine of healthy adults, may protect against urinary tract infection (UTI). Epidemiologic studies evaluating this relationship in humans are lacking. STUDY DESIGN: Prospective longitudinal cohort study. SETTING & PARTICIPANTS: 953 participants enrolled in the Cardiovascular Health Study. PREDICTOR: Uromodulin assayed using enzyme-linked immunosorbent assay in spot urine samples. OUTCOMES: Composite of outpatientUTI events or UTI-related hospitalizations and each of them individually identified using International Classification of Diseases, Ninth Revision (ICD-9) codes using negative binomial regression with robust standard errors adjusted for age, race, sex, body mass index, diabetes, estimated glomerular filtration rate, and urinary albumin and urinary creatinine excretion. RESULTS: Median uromodulin level was 25.9 (IQR, 17.3-38.9) μg/mL, mean age of participants was 78 years, 61% were women, and 15% were black. There were 331 outpatientUTI events and 87 UTI-related hospitalizations among 186 participants during a median 9.9 years of follow-up. Persons in the highest quartile (>38.93μg/mL) of uromodulin concentration had a significantly lower risk for the composite outcome (incidence rate ratio [IRR], 0.47; 95% CI, 0.29-0.79) compared with those in the lowest quartile (≤17.26μg/mL). This association remained significant for outpatientUTI events (highest vs lowest quartile even after excluding those with prior UTI: IRR, 0.42; 95% CI, 0.23-0.77). The direction of association with UTI hospitalization was similar, but not statistically significant (IRR, 0.78; 95% CI, 0.39-1.58). LIMITATIONS: Use of ICD-9 codes to identify outcomes and lack of generalizability to younger populations. CONCLUSIONS: High urinary uromodulin levels are associated with lower risk for UTI in older community-dwelling adults independent of traditional UTI risk factors. This finding supports prior laboratory data indicating a protective role of uromodulin against UTI. Further research is needed to understand if this may lead to new treatments to prevent or treat UTI.
Authors: Marcus D Säemann; Thomas Weichhart; Maximilian Zeyda; Günther Staffler; Michael Schunn; Karl M Stuhlmeier; Yuri Sobanov; Thomas M Stulnig; Shizuo Akira; Alexander von Gabain; Uwe von Ahsen; Walter H Hörl; Gerhard J Zlabinger Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: Lesley A Stevens; Josef Coresh; Christopher H Schmid; Harold I Feldman; Marc Froissart; John Kusek; Jerome Rossert; Frederick Van Lente; Robert D Bruce; Yaping Lucy Zhang; Tom Greene; Andrew S Levey Journal: Am J Kidney Dis Date: 2008-03 Impact factor: 8.860
Authors: Adinda Wellens; Corinne Garofalo; Hien Nguyen; Nani Van Gerven; Rikard Slättegård; Jean-Pierre Hernalsteens; Lode Wyns; Stefan Oscarson; Henri De Greve; Scott Hultgren; Julie Bouckaert Journal: PLoS One Date: 2008-04-30 Impact factor: 3.240
Authors: Pranav S Garimella; Mary L Biggs; Ronit Katz; Joachim H Ix; Michael R Bennett; Prasad Devarajan; Bryan R Kestenbaum; David S Siscovick; Majken K Jensen; Michael G Shlipak; Paulo H M Chaves; Mark J Sarnak Journal: Kidney Int Date: 2015-07-08 Impact factor: 10.612
Authors: Anna Reznichenko; Carsten A Böger; Harold Snieder; Jacob van den Born; Martin H de Borst; Jeffrey Damman; Marcory C R F van Dijk; Harry van Goor; Bouke G Hepkema; Jan-Luuk Hillebrands; Henri G D Leuvenink; Jan Niesing; Stephan J L Bakker; Marc Seelen; Gerjan Navis Journal: BMC Med Genet Date: 2012-09-05 Impact factor: 2.103
Authors: Benjamin A Neely; Katherine C Prager; Alison M Bland; Christine Fontaine; Frances M Gulland; Michael G Janech Journal: J Proteome Res Date: 2018-08-28 Impact factor: 4.466
Authors: Vasantha Jotwani; Pranav S Garimella; Ronit Katz; Rakesh Malhotra; Jeffrey Bates; Alfred K Cheung; Michel Chonchol; Paul E Drawz; Barry I Freedman; William E Haley; Anthony A Killeen; Henry Punzi; Mark J Sarnak; Mark S Segal; Michael G Shlipak; Joachim H Ix Journal: Am J Nephrol Date: 2020-09-09 Impact factor: 3.754
Authors: Pranav S Garimella; Alexandra K Lee; Walter T Ambrosius; Udayan Bhatt; Alfred K Cheung; Michel Chonchol; Timothy Craven; Amret T Hawfield; Vasantha Jotwani; Anthony Killeen; Henry Punzi; Mark J Sarnak; Barry M Wall; Joachim H Ix; Michael G Shlipak Journal: Eur Heart J Date: 2019-11-01 Impact factor: 35.855